ATE296357T1 - Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren - Google Patents

Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren

Info

Publication number
ATE296357T1
ATE296357T1 AT99915976T AT99915976T ATE296357T1 AT E296357 T1 ATE296357 T1 AT E296357T1 AT 99915976 T AT99915976 T AT 99915976T AT 99915976 T AT99915976 T AT 99915976T AT E296357 T1 ATE296357 T1 AT E296357T1
Authority
AT
Austria
Prior art keywords
coa reductase
hmg
reductase inhibitor
crystallization
reductase inhibitors
Prior art date
Application number
AT99915976T
Other languages
English (en)
Inventor
Zlatko Pflaum
Dusan Milivojevic
David Senica
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE296357(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of ATE296357T1 publication Critical patent/ATE296357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
AT99915976T 1998-02-18 1999-02-17 Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren ATE296357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800046A SI9800046A (sl) 1998-02-18 1998-02-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
PCT/IB1999/000808 WO1999042601A1 (en) 1998-02-18 1999-02-17 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Publications (1)

Publication Number Publication Date
ATE296357T1 true ATE296357T1 (de) 2005-06-15

Family

ID=20432203

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915976T ATE296357T1 (de) 1998-02-18 1999-02-17 Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren

Country Status (21)

Country Link
US (1) US6825015B1 (de)
EP (1) EP1054993B1 (de)
JP (2) JP2002504345A (de)
KR (1) KR100582620B1 (de)
CN (1) CN1206363C (de)
AT (1) ATE296357T1 (de)
AU (1) AU743619B2 (de)
BG (1) BG64289B1 (de)
CA (1) CA2321052A1 (de)
CZ (1) CZ297093B6 (de)
DE (1) DE69925459T2 (de)
HR (1) HRP20000541A2 (de)
HU (1) HUP0100820A3 (de)
IL (1) IL137782A0 (de)
PL (1) PL193510B1 (de)
RO (1) RO120922B1 (de)
RU (1) RU2235130C2 (de)
SI (2) SI9800046A (de)
SK (1) SK285074B6 (de)
WO (1) WO1999042601A1 (de)
YU (1) YU50100A (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030026920A (ko) * 1999-11-30 2003-04-03 비오갈 기오기스제르갸르 알티. 발효 브로스로부터 스타틴 화합물의 수집 방법
HUP0204005A3 (en) 1999-12-14 2003-05-28 Teva Gyogyszergyar Zartkoeruee Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them
SK12012002A3 (sk) * 2000-02-24 2003-02-04 Biogal Gyogyszergyar Rt. Spôsob purifikácie fermentačného bujónu
CZ20023201A3 (cs) 2000-03-03 2003-09-17 Plus Chemicals S. A. Způsob čištění lovastatinu a simvastatinu na produkt se sníženou hladinou dimerních nečistot
IN192861B (de) * 2000-06-30 2004-05-22 Ranbaxy Lab Ltd
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
TWI319707B (en) 2003-11-24 2010-01-21 Method of purifying pravastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
CN102384955B (zh) * 2010-09-01 2014-04-30 北京北大维信生物科技有限公司 人体血浆中HMG－CoA还原酶抑制剂的定量分析方法
RU2585233C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Промышленный способ получения компактина
RU2585234C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Способ получения компактина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294846A (en) 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
PT85109A (en) 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
DK0784605T3 (da) * 1995-08-03 2000-07-31 Dsm Nv Selektiv fremgangsmåde til deacyleringen af acylforbindelser
ES2131037T3 (es) * 1995-12-06 2001-12-16 Balkanpharma Razgrad Ad Procedimiento de preparacion de lovastatina.
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására

Also Published As

Publication number Publication date
DE69925459D1 (de) 2005-06-30
KR100582620B1 (ko) 2006-05-23
CN1291238A (zh) 2001-04-11
RO120922B1 (ro) 2006-09-29
CZ297093B6 (cs) 2006-09-13
CN1206363C (zh) 2005-06-15
EP1054993B1 (de) 2005-05-25
US6825015B1 (en) 2004-11-30
KR20010041024A (ko) 2001-05-15
HRP20000541A2 (en) 2001-12-31
BG104696A (en) 2001-07-31
HUP0100820A3 (en) 2003-07-28
JP2002504345A (ja) 2002-02-12
SI9800046A (sl) 1999-08-31
PL342513A1 (en) 2001-06-18
YU50100A (sh) 2003-07-07
DE69925459T2 (de) 2006-04-27
PL193510B1 (pl) 2007-02-28
SK11852000A3 (sk) 2001-05-10
BG64289B1 (bg) 2004-08-31
JP2005110693A (ja) 2005-04-28
SK285074B6 (sk) 2006-05-04
RU2235130C2 (ru) 2004-08-27
HUP0100820A2 (hu) 2001-08-28
CZ20002856A3 (cs) 2000-11-15
SI1054993T1 (en) 2005-10-31
IL137782A0 (en) 2001-10-31
AU743619B2 (en) 2002-01-31
EP1054993A1 (de) 2000-11-29
WO1999042601A1 (en) 1999-08-26
AU3438499A (en) 1999-09-06
CA2321052A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
ATE296357T1 (de) Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren
YU63602A (sh) Postupak za prečišćavanje fermentacionog bujona
ATE126829T1 (de) Verfahren zur herstellung von salzen des l- ornithins.
RU2000124064A (ru) Способ получения ингибиторов hmg-coa-редуктазы высокой степени чистоты
WO2001068893A3 (en) Soapstock hydrolysis and acidulation by acidogenic bacteria
ATE309262T1 (de) Verfahren zur herstellung von aufgereinigtem anthocyanin und kristallines anthocyanin
EP1233071A3 (de) Stickstoff enthaltende organische Zusammensetzung und diese enthaltende Düngemittel
DE3765157D1 (de) Verfahren zur herstellung von macrolid-derivaten.
DE69826852T8 (de) Verbessertes verfahren zur fermentativen herstellung von penicillin
EP0803576A3 (de) Verfahren zur Herstellung von Lipstatin und Tetrahydrolipstatin
EP0927755A3 (de) Haloacetoacetatreductase,Verfahren zur Herstellung und Verfahren zur Herstellung von Alcoholen damit
ID26888A (id) Proses produksi fermentasi cephalosporin
ATE232910T1 (de) Syntheseverfahren für inhibitoren der hmg-coa- reduktase
DE69828940D1 (de) Verbessertes verfahren zur fermentativen herstellung von cephalosporin
SE0003958D0 (sv) Method for growth of microorganisms
US5258290A (en) Fermentation process for the production of β-carboline derivatives by Myrothecium verrucaria
ATE145670T1 (de) Verfahren zur fermentativen herstellung von 2- hydroxyphenylessigsäure
WO2000052012A8 (en) A method for synthesizing porphyrin compounds
WO2002022849A3 (en) Enzymatic resolution of aryl- and thio-substituted acids
DE69619402D1 (de) Verfahren zur herstellung von methoximinophenylglyoxylsäure-derivaten
RU2001132333A (ru) Способ получения производных стероидных гликозидов RUSCUS ACULEATUS
KR940014801A (ko) 미생물이 생산하는 리보플라빈의 제조방법
WO2004038375A3 (en) Water soluble toxin produced by pfiesteria species
EP0795607A3 (de) Verfahren zur Herstellung einer Lakton
ATE420972T1 (de) Stereoselektiver prozess zur herstellung von nukleosidanalogen dioxolan-derivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1054993

Country of ref document: EP